Characterization of serum biomarkers for detection of early stage ovarian cancer

We have previously reported the identification of three ovarian cancer biomarker panels comprised of SELDI‐TOF‐MS peaks representing 14 differentially expressed serum proteins for the diagnosis of ovarian cancer. Using micro‐LC‐MS/MS, we identified five m/z peaks as transthyretin (TTR 13.9 kDa, TTR fragment 12.9 kDa), beta‐hemoglobin (Hb, 15.9 kDa), apolipoprotein AI (ApoAI, 28 kDa) and transferrin (TF, 79 kDa). Western and/or ELISA methods confirmed the differential expression of TTR, Hb, and TF, and multivariate analyses resulted in improving the detection of early stage ovarian tumors (low malignant potential and malignant; receiver operating characteristic, ROC 0.933) as compared to cancer antigen CA125 alone (ROC 0.833). Interestingly, when CA125 was included with our markers in the multivariate analysis, the ROC increased to 0.959. Furthermore, multivariate analysis with only the mucinous subtype of early stage ovarian tumors, showed our markers to greatly improve the detection of disease (ROC 0.959) as compared to CA125 alone (ROC 0.613). Interestingly, the combination of CA125 with our markers did not seem to further improve the detection of mucinous tumors (ROC 0.955). We conclude that TTR, Hb, ApoAI and TF, when combined with CA125 should significantly improve the detection of early stage ovarian cancer.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  D. Atallah,et al.  Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[4]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. L. Baldwin,et al.  Cancer incidence in a population of Jewish women at risk of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Mills,et al.  Early detection of ovarian cancer: promise and reality. , 2002, Cancer treatment and research.

[7]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[8]  J. Krejsek,et al.  Serum prealbumin, transferrin and alpha-1-acid glycoprotein in patients with gynecological carcinomas. , 1988, Neoplasma (Bratislava).

[9]  T. Imanishi.  Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury , 1981, Gastroenterologia Japonica.

[10]  J. Whitelegge,et al.  Transit Peptide Cleavage Sites of Integral Thylakoid Membrane Proteins* , 2003, Molecular & Cellular Proteomics.

[11]  E. Tarelli,et al.  Evaluation of an integrated strategy for proteomic profiling of skeletal muscle , 2004, Proteomics.

[12]  D. Swinkels,et al.  Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  K. Nicolaides,et al.  Serum CA125 at 11–14 weeks of gestation in women with morphologically normal ovaries , 2000, BJOG : an international journal of obstetrics and gynaecology.

[14]  B. Karlan,et al.  The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. , 1994, Gynecologic oncology.

[15]  D. Mutch.  Surgical management of ovarian cancer. , 2002, Seminars in oncology.

[16]  U Menon,et al.  Recent developments in ovarian cancer screening , 2000, Current opinion in obstetrics & gynecology.

[17]  Z. Kopczyński,et al.  The biochemical modification of the erythrocyte membranes from women with ovarian cancer. , 1998, British Journal of Cancer.

[18]  G. Palomaki,et al.  Reference distributions for the negative acute‐phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort , 1999, Journal of clinical laboratory analysis.

[19]  F. Sladek,et al.  Effect of dietary protein restriction on liver transcription factors. , 1996, The Biochemical journal.

[20]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[21]  E. Bastounis,et al.  Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[22]  D. Fishman,et al.  Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. , 2001, Gynecologic oncology.

[23]  B. Warshaw,et al.  Decreased serum transferrin concentration in children with the nephrotic syndrome: effect on lymphocyte proliferation and correlation with serum immunoglobulin levels. , 1984, Clinical immunology and immunopathology.

[24]  K. Grankvist,et al.  Plasma prealbumin in women with epithelial ovarian carcinoma. , 1994, Gynecologic and obstetric investigation.

[25]  A. Tefferi.  Diagnosing polycythemia vera: a paradigm shift. , 1999, Mayo Clinic proceedings.

[26]  S. Reddy,et al.  Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion , 2003, Proceedings of the National Academy of Sciences of the United States of America.